HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.

Abstract
Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous transplantation using marrow treated ex vivo with mafosfamide. At transplant, 7 patients were in chronic phase (5 in first, 2 in second) and 3 in accelerated phase. The median time to achieve 500 x 10(6)/l neutrophils was 32 days (range 17-72 days). A platelet count of 20 x 10(9)/l was achieved at a median of 40 days (range 24-151 days). After transplant, cytogenetic analysis revealed 100% Ph-negative marrow metaphases in 6 of 9 analyzable patients with a median duration of Ph-negative hematopoiesis of 6.5 months. After a median follow-up of 16 months (range 3-31 months), five patients evolved into blast crisis, two died of non-hematological causes, one is Ph-negative in chronic phase at +4 and one is in chronic phase, but Ph-positive, at +22. In conclusion, this pilot study demonstrates that: (1) engraftment can occur from Ph-negative stem cells selected by mafosfamide, (2) mafosfamide purging may induce a transient period of Ph-negative hematopoiesis, and (3) modifications of the purging procedure and post-transplant manipulations of the immune-hematopoietic system are required to prolong cytogenetic remission.
AuthorsC Carlo-Stella, L Mangoni, C Almici, C Caramatti, L Cottafavi, G P Dotti, V Rizzoli
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 14 Issue 3 Pg. 425-32 (Sep 1994) ISSN: 0268-3369 [Print] England
PMID7994267 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • mafosfamide
  • Cyclophosphamide
Topics
  • Adult
  • Bone Marrow (drug effects, pathology)
  • Bone Marrow Purging
  • Bone Marrow Transplantation
  • Chronic Disease
  • Cyclophosphamide (analogs & derivatives, pharmacology)
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells (pathology)
  • Humans
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (mortality, pathology, therapy)
  • Male
  • Middle Aged
  • Pilot Projects
  • Survival Rate
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: